卡博替尼联合多西他赛和泼尼松治疗转移性去势抵抗性前列腺癌
这是一项1/2期多中心研究,评估卡博替尼联合多西他赛/泼尼松在转移性去势抵抗性前列腺癌(mCRPC)患者中的安全性和疗效。1期确定最大耐受剂量(MTD)为卡博替尼40 mg,2期因入组缓慢提前终止,联合组(n=13)中位TTP 21.0个月优于单药组(n=12)的6.6个月(P=0.035),OS有获益趋势但未达统计学显著(23.8 vs 15.6个月,P=0.072)。
要点
- 卡博替尼联合多西他赛/泼尼松的MTD为40 mg每日。
- 剂量限制性毒性包括中性粒细胞减少性发热和手足综合征。
- 2期联合组TTP显著延长,但样本量小且提前终止。
核心结论
- 卡博替尼可安全联合多西他赛/泼尼松,可能增强疗效,但患者数有限。
研究设计与样本
- 1/2期多中心研究,纳入44例mCRPC患者。
- 1期剂量递增:卡博替尼20、40、60 mg每日联合多西他赛75 mg/m2每3周及泼尼松10 mg每日。
- 2期随机比较MTD卡博替尼联合方案与多西他赛/泼尼松单药。
主要发现
- 1期确定MTD为卡博替尼40 mg联合多西他赛/泼尼松。
- 剂量限制性毒性为中性粒细胞减少性发热和手足综合征,1例死于血栓栓塞事件。
- ≥3例患者出现3/4级骨髓抑制、低磷血症和神经病变。
- 1期研究中位TTP 13.6个月,中位OS 16.3个月。
- 2期联合组(n=13)中位TTP 21.0个月 vs 单药组(n=12)6.6个月(P=0.035),中位OS 23.8 vs 15.6个月(P=0.072)。
关键数值与推荐
- 卡博替尼MTD为40 mg每日联合多西他赛75 mg/m2每3周及泼尼松10 mg每日。
- 2期因入组缓慢提前终止。
临床怎么用
- 目前数据尚不支持临床常规使用卡博替尼联合多西他赛/泼尼松,需进一步大样本验证。
局限性
- 2期样本量小(联合组13例,单药组12例)且提前终止,结果需谨慎解读。
- 1期和2期总样本量仅44例,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m2 every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg). Based on the results of the phase 1 study, the investigation was expanded into a randomized study of docetaxel with prednisone (hereafter 'docetaxel/prednisone') plus the maximum tolerated dose (MTD) of cabozantinib compared with docetaxel/prednisone alone. RESULTS: A total of 44 men with mCRPC were enrolled in this phase 1/2 trial. An MTD of 40 mg cabozantinib plus docetaxel/prednisone was determined. Dose-limiting toxicities were neutropenic fever and palmar-plantar erythrodysesthesia, and there was one death attributable to a thromboembolic event. In addition, grade 3 or 4 myelosuppression, hypophosphataemia and neuropathy were seen in three or more patients. In the phase 1 study, the median time to progression (TTP) and overall survival (OS) time were 13.6 and 16.3 months, respectively. In the phase 2 study, which was terminated early because of poor accrual, the median TTP and OS favoured the combination (n = 13) compared to docetaxel/prednisone alone (n = 12; 21.0 vs 6.6 months; P = 0.035 and 23.8 vs 15.6 months; P = 0.072, respectively). CONCLUSION: Despite the limited number of patients in this study, preliminary data suggest that cabozantinib can be safely added to docetaxel/prednisone with possible enhanced efficacy.
引用
- Madan RA, Karzai FH, Al Harthy M, et al. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU Int. 2020. PMID: 32969563. doi:10.1111/bju.15227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。